What's in Sumitomo Pharma (Suzhou) Co., Ltd.'s pipeline?

Sumitomo Pharma (Suzhou) Co., Ltd. has 7 drugs in our index: 5 marketed, 0 filed, 2 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Sumitomo Pharma (Suzhou) Co., Ltd.'s portfolio?

Top competitors by shared drug class: Abbott, Acacia Pharma Ltd, Alexza Pharmaceuticals, Inc., Alkermes, Inc., All India Institute of Medical Sciences, Bhubaneswar.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/sumitomo-pharma-suzhou-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Sumitomo Pharma (Suzhou) Co., Ltd. — Portfolio Competitive Intelligence Brief

Sumitomo Pharma (Suzhou) Co., Ltd. pipeline: 5 marketed, 0 filed, 2 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

5 marketed 0 filed 2 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Usual dose treatment of Tandospirone	Usual dose treatment of Tandospirone	marketed	5-HT1A receptor agonist	5-HT1A receptor	Psychiatry/Neurology
Arotinolol Hydrochloride	Arotinolol Hydrochloride	marketed	Alpha-beta blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor	Cardiovascular
Risperidone tablets	Risperidone tablets	marketed	Atypical antipsychotic	Dopamine D2 receptor; Serotonin 5-HT2A receptor	Psychiatry/Neurology
Non arotinolol group	Non arotinolol group	marketed	Beta-blocker	Beta-adrenergic receptors	Cardiovascular
Metoprolol succinate sustained-release tablet	Metoprolol succinate sustained-release tablet	marketed
Lurasidone tablets	Lurasidone tablets	phase 3	Atypical antipsychotic	Dopamine D2 receptor, Serotonin 5-HT7 receptor	Psychiatry
Etoposide-Cisplatin combined chemotherapy	Etoposide-Cisplatin combined chemotherapy	phase 3	Combination chemotherapy		Oncology

Therapeutic area mix

Cardiovascular · 2
Psychiatry/Neurology · 2
Oncology · 1
Psychiatry · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Abbott · 1 shared drug class
Acacia Pharma Ltd · 1 shared drug class
Alexza Pharmaceuticals, Inc. · 1 shared drug class
Alkermes, Inc. · 1 shared drug class
All India Institute of Medical Sciences, Bhubaneswar · 1 shared drug class
AstraZeneca · 1 shared drug class
Benaroya Research Institute · 1 shared drug class
AbbVie · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Sumitomo Pharma (Suzhou) Co., Ltd.:

Cite this brief

Drug Landscape (2026). Sumitomo Pharma (Suzhou) Co., Ltd. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/sumitomo-pharma-suzhou-co-ltd. Accessed 2026-05-16.